<DOC>
	<DOCNO>NCT02645604</DOCNO>
	<brief_summary>Background : Malaria disease cause parasite . People get malaria bitten parasite-infected mosquito . A drug call artemether-lumefantrine ( AL ) treat malaria . Although iAL help make malaria problem less severe African country Mali , researcher want find malaria parasite become resistant drug . Objective : To test AL-resistant parasite child malaria Mali . Eligibility : AL resistance monitoring study : child age 2 17 year live Kenieroba , Mali , malaria . Blood collection substudy : healthy volunteer age 18 65 year . Design : Volunteers substudy blood take 6 time year . Study participant screen 1 finger-prick blood sample . Girls may pregnancy test . Baseline visit : Participants physical exam . Their vital sign temperature measure . They answer question symptom . They give blood sample . Participants get 6 dos AL 3 day . They take tablet form milk . Some participant also stay clinic 2 day . They catheter place vein . They blood take frequently . Participants follow-up visit 1 month . They may : Physical exam perform Vital sign temperature measure Symptom questionnaire administer Finger-prick blood sample and/or regular blood sample take Pregnancy test give Antimalarial medication AL provide .</brief_summary>
	<brief_title>Artemether-lumefantrine Resistance Monitoring Children With Uncomplicated Plasmodium Falciparum Malaria Mali</brief_title>
	<detailed_description>Artemether-lumefantrine ( AL ) replace artesunate + amodiaquine frontline artemisinin ( ART ) combination therapy ( ACT ) uncomplicated Plasmodium falciparum malaria Mali . It know whether parasite develop resistance AL Mali , study naturally-acquired immunity sickle-cell trait reduce malaria risk parasite density pediatric study population . AL Resistance Monitoring Study : To monitor emerge AL resistance vivo lumefantrine ( LF ) resistance ex vivo , conduct standard WHO-recommended protocol measure AL resistance rate next 4 year . We enroll child age 2-17 year uncomplicated falciparum malaria parasite count 2,000 200,000 parasite per microliter , treat AL D0 , D1 , D2 , confirm adequate LF plasma concentration Day 7 , monitor malaria symptom recurrent parasitemias D0 , D1 , D2 , D3 , D7 , D14 , D21 , D28 . In related laboratory study , use blood sample take time enrollment recrudescence measure parasite susceptibility LF antimalarial drug ex vivo ; investigate genetic transcriptional determinant parasite response AL vivo LF ex vivo ; prepare cryopreserved parasite future work drug action resistance mechanism . Parasite Clearance Substudy : We recently discover agedependent acceleration parasite clearance rate Malian child , postulate mediate IgG specific Plasmodium falciparum erythrocyte membrane protein 1 ( PfEMP1 ) , parasite main virulence factor surface infect red blood cell ( iRBCs ) . We hypothesize ART exposure induces premature expression PfEMP1 surface circulate ring-iRBCs vivo . To test hypothesis , calculate parasite clearance rate subset subject relatively high parasite density , relate rate ability autologous IgG recognize ring-iRBCs first 8 hour ART exposure vivo . In subset patient , also explore whether AL induces parasite dormancy vivo remove parasite H0 , H6 , H24 , H48 , D3 , D7 , D14 follow AL therapy , clone quantify number viable parasite . Blood Collection Study : We find sickle-cell trait ( HbAS ) , like naturally-acquired humoral immunity , reduce malaria risk parasite density study population , protection associate abnormal PfEMP1 display iRBC surface . To elucidate molecular mechanism phenotype explore may synergize naturally-acquired IgG response , investigate whether development PfEMP1 traffic machinery impair HbAS compare normal homozygous hemoglobin A ( HbAA ) red blood cell ( RBCs ) . To test , purify parasite isolates child malaria , inoculate HbAA HbAS RBCs healthy adult donor , follow intraerythrocytic development use flow cytometry electron microscopy .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>INCLUSION CRITERIA : Subject AL Resistance Monitoring Study Resident Kenieroba Age 2 17 year Uncomplicated falciparum malaria , confirm presence asexual P. falciparum parasite blood film Asexual P. falciparum count 2,000 200,000/ microliters ( inclusive ) screen Tympanic axillary temperature great equal 37.5 ( Infinite ) C history fever previous 24 hour Written inform consent child parent guardian , assent child age 1417 year Subject Parasite Clearance Substudy Enrolled AL Resistance Monitoring Study Asexual P. falciparum count great equal 10,000/ microliters screen Hb level great equal 7 g/dL Subject Blood Collection Study Age 18 65 year Healthyappearing Hb level great equal 7 g/dL EXCLUSION CRITERIA : Subject AL Efficacy Study Signs severe malaria , define one following : Blantyre Coma Scale less equal 3/5 child Witnessed convulsion Severe prostration Shock ( poor perfusion , cool periphery ) Hb &lt; 5 g/dL Jaundice Respiratory distress ( labored breathing , nasal flaring , intercostal retraction ) Anuria 24 hour Repetitive vomit Cessation eat drink Acute illness uncomplicated falciparum malaria require treatment Presence P. ovale P. malariae parasite blood film Severe malnutrition : http : //www.who.int/childgrowth/standards/Technical_report.pdf Pregnancy breastfeed infant Planning become pregnant next 1 month History take ACT previous 14 day Known hypersensitivity artemether LF Coadministration strong inducer CYP3A4 rifampin , carbamazepine , phenytoin , St. John wort Splenectomy Any condition opinion investigator would render patient unable comply protocol ( e.g. , psychiatric disease ) Any health condition opinion investigator would confound data analysis ( e.g. , HIV infection ) pose unnecessary exposure risk subject Subject Parasite Clearance Substudy Prior enrollment Parasite Clearance Substudy current transmission season Subject Blood Collection Study P. falciparum infection , determine thick blood smear examination ( unless subject screen inclusion mosquito infectivity study , case parasitemia , detect RDT smear , inclusion criterion ) History take ACT previous 28 day</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 13, 2016</verification_date>
	<keyword>Artemisinin Combination Therapy ( ACT )</keyword>
</DOC>